-
Medical journals
- Career
Study COPDGene Redefines Diagnostic Criteria of Chronic Obstructive Pulmonary Disease
28. 5. 2020
Chronic obstructive pulmonary disease ranks among the top causes of morbidity and mortality worldwide. Current diagnostic criteria for the disease are based exclusively on spirometric examination. Increasing evidence, however, suggests that a significant number of patients show signs of chronic obstructive pulmonary disease without pathological findings on spirometry. The analysis of the COPDGene study thus proposes expanding the diagnostic criteria to include additional parameters.
Introduction
Current diagnostic criteria for chronic obstructive pulmonary disease (COPD) rely primarily on the presence of obstructive ventilatory disorder on a spirometric examination, combined with a history of tobacco product abuse and the presence of clinical symptoms. Some previous studies have suggested that a group of smokers display clinical symptoms and structural changes akin to COPD, but without the presence of obstructive disorder on a spirometric examination. Over time, these individuals may progress to a spirometrically confirmed COPD.
The goal of the COPDGene® study analysis was to redefine the diagnostic criteria of COPD by adding key parameters that could help identify additional individuals at risk of COPD without a positive finding on spirometric examination.
Methodology
A total of 8,784 current or former smokers who participated in phase I of the COPDGene® study met the inclusion criteria for the analysis. Four key parameters were evaluated in these patients: environmental exposure (cigarette smoking), clinical symptoms (dyspnea and/or chronic bronchitis), abnormal findings on CT (emphysema, gas trapping, and/or airway wall thickening), and abnormal spirometric findings.
Using these key parameters, patients were divided into eight groups (A–H), with the common parameter being active or former cigarette smoking. Group A, comprising patients with only the parameter of tobacco smoke exposure, served as the reference group. The primary aim of the study was to assess the risk of disease progression (a decrease in FEV1 by > 350 ml over 5 years) and all-cause mortality.
Results
According to current classification criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 4,062 out of 8,784 analyzed individuals (46%) met the criteria for disease. Based on COPDGene® diagnostic criteria, which classify individuals into groups of possible, probable, and definite COPD, an additional 3,144 individuals would be included. According to the new criteria, a total of 82% of patients would be classified into the possible, probable, or definite COPD group.
In these groups, an increased risk of disease progression and all-cause mortality was observed. A trend of increasing risk of disease progression and all-cause mortality with accumulating risk factors was noted in the groups, with the highest risk observed in group H (for progression, odds ratio [OR] 2.82; 95% confidence interval [CI] 2.18–3.66; for mortality, OR 5.18; 95% CI 4.15–6.48).
Conclusion
A substantial number of smokers with respiratory symptoms and abnormalities on CT scans do not meet spirometric diagnostic criteria for COPD. These patients are nonetheless at significant risk of spirometrically confirmed disease progression and all-cause mortality. Therefore, the scientific team that conducted the COPDGene® study analysis proposes a redefinition of the diagnostic criteria for COPD by integrating parameters of environmental exposure, clinical symptoms, abnormal CT findings, and spirometric examination.
Expanding the diagnostic criteria could potentially capture a greater number of COPD patients who do not meet the spirometric criteria for diagnosis, providing an opportunity for current and future therapeutic interventions to successfully slow or halt the progression of the disease.
(holi)
Source: Lowe K. E., Regan E. A., Anzueto A. et al. COPDGene® 2019: Redefining the diagnosis of chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis 2019 Nov; 6 (5): 384–399, doi: 10.15326/jcopdf.6.5.2019.0149.
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
Labels
Pneumology and ftiseology
Popular this week- Night Shifts May Pose a Higher Risk of Asthma for Women
- Twilight of Radiologists? Will They Be Replaced by Artificial Intelligence?
- Talking without vocal cords? A new AI-supported technology may help
- How Compassion Fatigue Threatens Doctors and Other Healthcare Workers
- Could Artificial Intelligence Help with Emergency Department Triage in the Future?
Recommended for you- Dupilumab – The First Biologic Umbrellaing Type 2 Inflammation Treatment: How Does It Work and Who Is It For?
- Omalizumab and Treatment of Severe Refractory Asthma in Pregnant Women
- Should We Test for Alpha-1-Antitrypsin in All COPD Patients?
- Spiolto Respimat System – Innovation for Easier Inhalation
- Lorlatinib as an Alternative to CNS Radiotherapy in Patients with NSCLC − Case Studies
- Immunotherapy of Cancer Diseases
Login#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career